Gianrico Farrugia, President and CEO at Mayo Clinic, shared a post on LinkedIn:
“Today, Mayo Clinic announced a new theranostics research collaboration with GE HealthCare to support new therapies for patients with advanced prostate cancer.
Learn about the MI-BET (Molecular Imaging Biomarker-Based End of Therapy Trial) study, which is designed to evaluate where imaging- and biomarker- informed insights can advance more personalized cures.”
Other articles about Prostate Cancer on OncoDaily.